# QL1706 Plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Phase II Trial

> **NCT07286253** · PHASE2 · RECRUITING · sponsor: **Affiliated Cancer Hospital & Institute of Guangzhou Medical University** · enrollment: 50 (estimated)

## Conditions studied

- Neoadjuvant Treatment for Locally Advanced Cervical Cancer

## Interventions

- **DRUG:** Drug: Drug: QL1706 5mg/kg, iv drip,d1,Q3W;Albumin-Bound Paclitaxel 260mg/m2, iv drip, d1, Q3W;Cisplatin50mg/m2, iv drip, d1, Q3W;Carboplatin AUC 5 ivdrip, d1, Q3W

## Key facts

- **NCT ID:** NCT07286253
- **Lead sponsor:** Affiliated Cancer Hospital & Institute of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-28
- **Primary completion:** 2027-09-30
- **Final completion:** 2028-03-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07286253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07286253, "QL1706 Plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Phase II Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07286253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*